ALS

All articles by ALS

MLB Network’s Sarah Langs pitches fans on #FistBumps4ALS campaign
MLB Network’s Sarah Langs pitches fans on #FistBumps4ALS campaign
Lecia Bushak
May 5, 2023
3:24 pm

Sarah Langs started #FistBumps4ALS on social media to raise money for ALS research.

FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS
Jack O'Brien
April 25, 2023
3:55 pm

The FDA’s decision came just over a month after an advisory committee issued a mixed vote on Tofersen.

Amylyx reports impressive early success for newly approved ALS drug Relyvrio
Amylyx reports impressive early success for newly approved ALS drug Relyvrio
Jack O'Brien
March 14, 2023
10:05 am

Thanks to the revenue beat, Amylyx’s stock is trading up more than 20% in the early morning session Tuesday.

Amylyx counters Wall Street noise, cites demand for ALS drug
Amylyx counters Wall Street noise, cites demand for ALS drug
Marc Iskowitz
February 14, 2023
3:17 pm

The firm’s ALS drug launch is going better than expected, execs said. An insurer’s coverage refusal had led to negative Wall Street chatter.

Cigna says it won’t cover Amylyx’s ALS drug Relyvrio
Cigna says it won’t cover Amylyx’s ALS drug Relyvrio
Jack O'Brien
February 8, 2023
3:58 pm

The insurance giant considers Relyvrio to be “experimental, investigational or unproven” for any use.

Netflix vet Steve Swasey dies after battle with ALS
Netflix vet Steve Swasey dies after battle with ALS
Diana Bradley
November 18, 2022
2:38 pm

PR pros who have worked with Swasey are paying tribute to him on social media.

Amylyx ALS drug Relyvrio wins FDA nod, but price raises eyebrows
Amylyx ALS drug Relyvrio wins FDA nod, but price raises eyebrows
Marc Iskowitz
September 30, 2022
3:53 pm

On a call with analysts Friday morning, the company defended the $158,000 price tag and carved out some wiggle room on an earlier withdrawal pledge.

FDA said to be lining up approval of Amylyx’s ALS drug
FDA said to be lining up approval of Amylyx’s ALS drug
Marc Iskowitz
September 13, 2022
9:34 am

After adcomm’s unprecedented about-face, drug candidate sees path to blockbuster status.

Amylyx’s ALS drug would not be cost-effective if priced like another ALS drug on the market
Amylyx’s ALS drug would not be cost-effective if priced like another ALS drug on the market
Marc Iskowitz
June 14, 2022
2:42 pm

The pricing watchdog ICER believes policymakers should debate short-term pricing options until the drug’s benefits can be ascertained.

Syneos Health leader and ALS advocate Lisa Stockman-Mauriello dies at 52
Syneos Health leader and ALS advocate Lisa Stockman-Mauriello dies at 52
Marc Iskowitz
August 5, 2021
5:40 pm

While battling ALS, she fought to change the way biotech allows access to experimental drugs. In doing so, she not only drew more attention to the disease, but also broke barriers to expanded access.

  • From Our Partners